Global Respiratory Partnering 2012-2018: Deal trends, players and financials

Publisher Name :
Date: 01-Oct-2018
No. of pages: 800
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Respiratory Partnering 2012-2018: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies

Global Respiratory Partnering 2012 to 2018 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Trends in Respiratory partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Respiratory partnering agreement structure

Respiratory partnering contract documents

Top Respiratory deals by value

Most active Respiratory dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2012 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Respiratory deals since 2012. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Respiratory deals since 2012 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2012. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.

Report scope

Global Respiratory Partnering 2012 to 2018 is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.

Global Respiratory Partnering 2012 to 2018 includes:

Trends in Respiratory dealmaking in the biopharma industry since 2012

Analysis of Respiratory deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Respiratory deal contract documents

Comprehensive access to over 3500 Respiratory deal records

The leading Respiratory deals by value since 2012

Most active Respiratory dealmakers since 2012

The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.

In Global Respiratory Partnering 2012 to 2018, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Respiratory Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 400 respiratory deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Respiratory Partnering 2012 to 2018 provides the reader with the following key benefits:

In-depth understanding of Respiratory deal trends since 2012

Access Respiratory deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Respiratory partner companies

Comprehensive access to over 750 links to actual Respiratory deals entered into by the world's biopharma companies

Indepth review of Respiratory deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Respiratory opportunities

Uncover companies actively partnering Respiratory opportunities

Global Respiratory Partnering 2012-2018: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Respiratory dealmaking
2.1. Introduction
2.2. Respiratory partnering over the years
2.3. Respiratory partnering by deal type
2.4. Respiratory partnering by industry sector
2.5. Respiratory partnering by stage of development
2.6. Respiratory partnering by technology type
2.7. Respiratory partnering by therapeutic indication

Chapter 3 -Financial deal terms for Respiratory partnering
3.1. Introduction
3.2. Disclosed financials terms for Respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates

Chapter 4 - Leading Respiratory deals and dealmakers
4.1. Introduction
4.2. Most active in Respiratory partnering
4.3. List of most active dealmakers in Respiratory
4.4. Top Respiratory deals by value

Chapter 5 - Respiratory contract document directory
5.1. Introduction
5.2. Respiratory partnering deals where contract document available

Chapter 6 - Respiratory dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Respiratory therapeutic target

Appendices
Appendix 1 - Directory of Respiratory deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Respiratory deals by deal type 2012 to 2018
Appendix 3 - Directory of Respiratory deals by stage of development 2012 to 2018
Appendix 4 - Directory of Respiratory deals by technology type 2012 to 2018
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Respiratory partnering since 2012
Figure 2: Respiratory partnering by deal type since 2012
Figure 3: Respiratory partnering by industry sector since 2012
Figure 4: Respiratory partnering by stage of development since 2012
Figure 5: Respiratory partnering by technology type since 2012
Figure 6: Respiratory partnering by indication since 2012
Figure 7: Respiratory deals with a headline value
Figure 8: Respiratory deals with upfront payment values
Figure 9: Respiratory deals with milestone payment
Figure 10: Respiratory deals with royalty rates
Figure 11: Active Respiratory dealmaking activity- 2012 to 2018
Figure 12: Top Respiratory deals by value since 2012
  • Global Carbocisteine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 102
    According to our LPI (LP Information) latest study, the global Carbocisteine market size was valued at US$ 55 million in 2023. With growing demand in downstream market, the Carbocisteine is forecast to a readjusted size of US$ 76 million by 2030 with a CAGR of 4.9% during review period. The research report highlights the growth potential of the global Carbocisteine market. Carbocisteine are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Bovine Respiratory Disease Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 120
    Report Overview: Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for......
  • Global Ambroxol Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 91
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ambroxol market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Teva - Bayer - Novartis - Mylan - Bidachem - Hanmi - Hexal Pharma - Sris Pharmaceuticals - Hubei Ocean Biotechnology - DM Pharma......
  • Global Carbocisteine Professional Survey Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 3280 Onwards        Pages: 101
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Carbocisteine Market Research Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 2680 Onwards        Pages: 136
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Bovine Respiratory Disease Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 09-Nov-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Bovine Respiratory Disease Treatment market: According to our latest research, the global Bovine Respiratory Disease Treatment market looks promising in the next 5 years. As of 2022, the global Bovine Respiratory Disease Treatment market was estimated at USD 1748.69 million, and it's anticipated to reach USD 2423.79 million in 2028, with a CAGR of 5.59% during the forecast years. Bovine respiratory disease (BRD) is a multifactorial and complex diseas......
  • Respiratory Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 200
    Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding......
  • Global Drugs For Respiratory Syncytial Virus (Rsv) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Sep-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Drugs For Respiratory Syncytial Virus (Rsv) market: According to our latest research, the global Drugs For Respiratory Syncytial Virus (Rsv) market looks promising in the next 5 years. As of 2022, the global Drugs For Respiratory Syncytial Virus (Rsv) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and......
  • Global Ambroxol Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Sep-2023        Price: US 3380 Onwards        Pages: 127
    Market Overview of Global Ambroxol market: According to our latest research, the global Ambroxol market looks promising in the next 5 years. As of 2022, the global Ambroxol market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Ambroxol market, with a systematical descriptio......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs